Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma

Ogiwara, Yamato; Nakagawa, Makoto; Nakatani, Fumihiko; Uemura, Yukari; Zhang, Rong; Kudo-Saito, Chie

doi:10.1016/j.canlet.2022.215690

Cited by 16 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, immunotherapy has great potential in the treatment of human malignant tumors ( Yang, 2015 ; Kennedy and Salama, 2020 ). Immunotherapy can effectively improve the OS prognosis ( Chen et al, 2021 ; Ogiwara et al, 2022 ). Studies have shown that PD-1, PD-L1, and CTLA-4 affect the progression of OS, and representative immunotherapy drugs include pembrolizumab/nivolumab (PD-1 inhibitor), ipilimumab (CTLA-4 inhibitor), and BMS-936559 (PD-L1 inhibitor) ( Vilain et al, 2017 ; Tawbi et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma

Song

Bai

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Copper-induced cell death, a form of apoptosis, has been extensively investigated in human diseases. Recent studies on the mechanisms underlying copper-induced cell death have provided innovative insights into copper-related toxicity in cells, and this form of programmed cell death was termed cuproptosis. Herein, we conducted a comprehensive analysis to determine the specific role of cuproptosis in osteosarcoma. Using consensus clustering analysis, patients with osteosarcoma from the TARGET database were classified into subgroups with distinct cuproptosis-based molecular patterns. Accordingly, these patients displayed diverse clinicopathological features, survival outcomes, tumor microenvironment (TME) characteristics, immune-related scores, and therapeutic responses. Furthermore, we constructed a cuproptosis-based risk signature and nomogram, as well as developed a cuproptosis score for improved patient characterization. The prognostic model and cuproptosis score were well validated and confirmed to efficiently distinguish high- and low-risk patients, thereby affording great predictive value. Finally, we verified the abnormal expression of prognostic CUG in OS patients by immunohistochemistry. In conclusion, we suggest that cuproptosis may play an important role in regulating the tumor microenvironment features, tumor progression and the long-term prognosis of osteosarcoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma

Song

Bai

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…88 Osteosarcoma cells have been shown to be readily eliminated by NK cells in some preclinical studies. 89,90 For example, cultivation of NKs from normal donors with osteosarcoma feeder cells for one week resulted in a median killing effect of approximately 46.1%. 91,92 Notably, this cytotoxicity was not associated with the expression levels of NK receptor ligands but was significantly suppressed through the exposure of NKs to anti-DNAM-1 and anti-NKG2D antibodies.…”

Section: The Immune Microenvironment Of Osteosarcomamentioning

confidence: 99%

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Tian

Cao

et al. 2023

Bone Res

View full text Add to dashboard Cite

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding the efforts of researchers, its five-year survival rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy has shown certain advantages over traditional tumor treatments in inhibiting metastasis. Therefore, managing the immune microenvironment in osteosarcoma can provide novel and valuable insight into the multifaceted mechanisms underlying the heterogeneity and progression of the disease. Additionally, given the advances in nanomedicine, there exist many advanced nanoplatforms for enhanced osteosarcoma immunotherapy with satisfactory physiochemical characteristics. Here, we review the classification, characteristics, and functions of the key components of the immune microenvironment in osteosarcoma. This review also emphasizes the application, progress, and prospects of osteosarcoma immunotherapy and discusses several nanomedicine-based options to enhance the efficiency of osteosarcoma treatment. Furthermore, we examine the disadvantages of standard treatments and present future perspectives for osteosarcoma immunotherapy.

show abstract

“…[104][105][106][107] T cell-mediated cellular immunity makes a valuable contribution toward the fight against tumor cells, and natural killer (NK) cell-mediated natural immunity is the first line of defense against tumors. 108 Due to the development of new tumor molecular biology techniques and the establishment of immunoassay indicators, doctors can accurately assess quantitative and qualitative changes in tumor molecules and cellular immune functions. [109][110][111] Moreover, immunotherapy can play an important role along with traditional surgery, radiotherapy, and chemotherapy.…”

Section: Immunotherapymentioning

confidence: 99%

Current Status and Prospects of Clinical Treatment of Osteosarcoma

Jiang¹,

Liu

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Osteosarcoma, one of the common malignant tumors in the skeletal system, originates in mesenchymal tissue, and the most susceptible area of occurrence is the metaphysis with its abundant blood supply. Tumors are characterized by highly malignant spindle stromal cells that can produce bone-like tissue. Most of the osteosarcoma are primary, and a few are secondary. Osteosarcoma occurs primarily in children and adolescents undergoing vigorous bone growth and development. Most cases involve rapid tumor development and early blood metastasis. In recent years, research has grown in the areas of molecular biology, imaging medicine, biological materials, applied anatomy, surgical techniques, biomechanics, and comprehensive treatment of tumors. With developments in molecular biology and tissue bioengineering, treatment methods have also made great progress, especially in comprehensive limb salvage treatment, which significantly enhances the quality of life after surgery and improves the 5-year survival rate of patients with malignant tumors. This article provides a review of limb salvage, immunotherapy, gene therapy, and targeted therapy from traditional amputation to neoadjuvant chemotherapy, providing a reference for current clinical treatments for osteosarcoma.

show abstract

Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma

Cited by 16 publications

References 34 publications

Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma

Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma

Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment

Current Status and Prospects of Clinical Treatment of Osteosarcoma

Contact Info

Product

Resources

About